

Yeast and human protein extracts for mass spectrometry method development and instrument validation



Sergei Saveliev, Ethan Strauss, Mike Rosenblatt and Marjeta Urh

Promega Corporation, Madison, WI

1. Introduction

To test protein mass spec sample preparation procedures and validate mass spec instrument performance, complex biological samples are required. Total cell protein extracts provide this desired sample complexity. However, to be compatible with mass spec applications, such extracts should meet a number of design requirements:


- ✓ compatibility with LC/MS (free of detergents, etc.)
- ✓ high protein integrity (minimal level of protein degradation and non-biological PTMs)
- ✓ compatibility with common sample preparation methods such as proteolysis, PTM enrichment and mass-tag labeling
- ✓ Lot-to-lot reproducibility

Here we describe total protein extracts from yeast and human cells that meet the above criteria. Two extract formats have been developed:

- **Intact protein extracts; primary use - sample preparation method development and optimization**
- **Pre-digested extracts (peptides); primary use - instrument validation and performance monitoring**


3. Intact extracts for mass spec method development

Suitable for proteolysis



Efficient digestion with trypsin.

Proteome fractionation



Peptide and protein identifications


| Extract | Unique peptides | Proteins |
|---------|-----------------|----------|
| Yeast | 11924 | 1525 |
| Human | 15576 | 2075 |

Q Exactive (Thermo), 2h gradient

Phosphopeptide enrichment

| Extract | Total peptides | Phosphopeptides | % of phosphopeptides |
|---------|----------------|-----------------|----------------------|
| Yeast | 2502 | 1715 | 68.5% |
| Human | 1768 | 1537 | 87% |

Labeling with mass tags




Three aliquots of the digested extract were individually labeled with the indicated TMT tag and mixed at 10:5:1 ratio. The data show good correlation between observed and expected protein quantitation levels.

4. Extract reproducibility

Protein and peptide composition reproducibility

| Extract | Protein overlap | | Peptide overlap | |
|---------|-----------------------------|---------------------------|-----------------------------|---------------------------|
| | Samples from different lots | Samples from the same lot | Samples from different lots | Samples from the same lot |
| Yeast | 90.5% | 90% | 79.3% | 78.5% |
| Human | 79.6% | 79.5% | 57.9% | 58.1% |

Protein Venn diagram
Human extract lots



Quantitation via spectral counting

| Protein | Yeast extract batches Spectral counting | | | Human extract batches Spectral counting | | | |
|-----------|---|-----|-----|---|-----|-----|-----|
| | #1 | #2 | #3 | #1 | #2 | #3 | |
| YBR118W | 358 | 375 | 368 | ENOA | 137 | 127 | 140 |
| YGR192C | 378 | 344 | 335 | HS90B | 155 | 157 | 153 |
| YCR012W | 369 | 336 | 304 | ACTG | 116 | 113 | 113 |
| YAL005C | 307 | 371 | 336 | HS90A | 134 | 130 | 129 |
| YBR196C | 153 | 153 | 146 | PRKDC | 126 | 129 | 116 |
| YLR249W | 150 | 129 | 128 | TBB5 | 96 | 96 | 99 |
| YDL145C | 23 | 22 | 25 | IF2P | 18 | 17 | 17 |
| YDR261C-D | 31 | 30 | 28 | ANXA2 | 21 | 23 | 23 |
| YKL035W | 31 | 26 | 32 | DLDH | 19 | 16 | 18 |
| YOR375C | 28 | 32 | 28 | PDIA4 | 21 | 27 | 22 |
| YDL195W | 21 | 22 | 21 | PPIB | 20 | 17 | 16 |
| YDR023W | 26 | 24 | 23 | BLVRB | 20 | 21 | 23 |
| YHR064C | 29 | 29 | 28 | AN32A | 21 | 19 | 19 |

Quantitation via SRM assay
Courtesy by Dr. Koomen, Moffitt Cancer Center

| Protein | Peptide | Batch | Normalized abundance* |
|--------------|--------------|-------|-----------------------|
| ABL1_HUMAN | EISDIVOR | A | 1.00 |
| | | B | 1.23 |
| | | C | 0.99 |
| SHC1_HUMAN | ALDFNTR | A | 0.85 |
| | | B | 1.00 |
| | | C | 1.10 |
| STAT3_HUMAN | TLTDEELADWK | A | 1.10 |
| | | B | 0.83 |
| | | C | 1.00 |
| STAT5A_HUMAN | LSPAPGLFVSAR | A | 0.92 |
| | | B | 1.09 |
| | | C | 1.00 |
| | YYTPVLAK | A | 1.00 |
| | | B | 1.09 |
| | | C | 0.93 |

*GAPDH normalized data


The extract lots show high reproducibility with respect to protein composition and abundance

2. The extract description

Source

Yeast extract – from *Saccharomyces cerevisiae* ~6,600 ORFs; all proteins quantified previously.

Human extract – from K562 cells
Complex human proteome with a large dynamic range.



A comparison of alternative extract preparations

| Extraction method | Protein degradation (% of nonspecific breaks) | Trypsin inhibition by extraction agent |
|-------------------------------------|---|---|
| Urea | 2% | Lack of inhibition (10% missed cleavages) (Urea was diluted to 1M prior to digestion) |
| Protease inhibitor cocktail (Roche) | 20% | Strong inhibition (55.9% missed cleavages) |
| GuCl | Not tested | Strong inhibition (44.4% missed cleavages at 0.5M GuCl concentration) |

Non-biological PTMs in Urea-extracted proteins

| Extract | Carbamylated peptides | Deamidation spectra | Oxidation spectra |
|---------|-----------------------|---------------------|-------------------|
| Yeast | 0.12% | 8% | 2% |
| Human | 0.15% | 4.6% | 0.7% |

Carbamylation was prevented by reducing proteins at low temperature (37°C versus 55°C-65°C). The temperature did not affect reduction efficiency.

Urea allowed for extraction of proteins with minimal level of degradation or non-biological PTMs without adverse effects on downstream sample preparation steps.


4. Pre-digested extracts for instrument validation

Features



- ✓ Ready for analysis - no need to reduce, alkylate, digest, or clean-up the sample
- ✓ Efficiently digested (less than 8% missed cleavages)
- ✓ Highly pure (SPE C₁₈ clean-up)
- ✓ Lyophilized

Applications

- ✓ Instrument method optimization and validation
- ✓ Instrument performance monitoring
- ✓ Inter- and intralaboratory benchmarking



| Instrument, laboratory and MS method | Pre-digested extract | Identified unique peptides | Identified proteins |
|--------------------------------------|----------------------|----------------------------|---------------------|
| Instrument #1, Lab #1, method #1 | yeast | 12427 | 1567 |
| | human | 18040 | 2370 |
| Instrument #1, Lab #2, method #2 | yeast | 27491 | 3096 |
| | human | 46018 | 4664 |
| Instrument #2, Lab #3, method #3 | yeast | 11233 | 1220 |
| | human | 10344 | 1588 |
| Instrument #3, Lab #4, method #4 | yeast | 14064 | 2703 |
| | human | 19531 | 3885 |



5. Conclusions

- We developed MS ready total yeast and human protein extracts
- Our method allows for protein recovery with high reproducibility and minimal level of protein degradation or non-biological PTMs
- The extracts are provided in two ready-to-use alternative formats
 - Intact protein extracts are designed for sample preparation method development and optimization
 - Pre-digested extracts (peptides) serve to meet the need of instrument validation and performance monitoring
- The extracts show excellent performance in various applications and provide conditions for comprehensive LC/MS instrument validation and method development